SABS vs. CRIS, SGMO, ESLA, DYAI, CYTH, OKYO, NKGN, SRZN, INKT, and TARA
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Curis (CRIS), Sangamo Therapeutics (SGMO), Estrella Immunopharma (ESLA), Dyadic International (DYAI), Cyclo Therapeutics (CYTH), OKYO Pharma (OKYO), NKGen Biotech (NKGN), Surrozen (SRZN), MiNK Therapeutics (INKT), and Protara Therapeutics (TARA). These companies are all part of the "biological products, except diagnostic" industry.
SAB Biotherapeutics (NASDAQ:SABS) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation.
In the previous week, Curis had 10 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 12 mentions for Curis and 2 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.34 beat Curis' score of -0.24 indicating that SAB Biotherapeutics is being referred to more favorably in the media.
SAB Biotherapeutics has higher earnings, but lower revenue than Curis.
Curis has a net margin of -473.04% compared to SAB Biotherapeutics' net margin of -1,884.10%. SAB Biotherapeutics' return on equity of -144.66% beat Curis' return on equity.
7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 26.0% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 5.7% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
SAB Biotherapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, meaning that its share price is 259% more volatile than the S&P 500.
SAB Biotherapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 267.30%. Curis has a consensus price target of $37.33, suggesting a potential upside of 122.22%. Given SAB Biotherapeutics' higher possible upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Curis.
Curis received 668 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 73.91% of users gave SAB Biotherapeutics an outperform vote while only 67.55% of users gave Curis an outperform vote.
Summary
Curis beats SAB Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
